Key facts
- This page summarizes Jerel Davis's Form 4 filing for Turnstone Biologics Corp. (TSBX).
- 5 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Aug 2025, 16:06.
Jerel Davis - 08 Aug 2025 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)
- Reporting relationship
- Director
- Issuer ticker
- TSBX
- Reported as of
- 08 Aug 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Aug 2025, 16:06:58 UTC
- Prior SEC filing
- 02 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jerel Davis
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jerel Davis filed Form 4 for Turnstone Biologics Corp. (TSBX) on 08 Aug 2025.
Change
- Previous filing in this sequence was filed on 02 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001745958
Primary reporting owner
Jerel Davis
- Relationship
- Director
- Address
- C/O TURNSTONE BIOLOGICS CORP., 1110 NORTH VIRGIL AVENUE PMB 94659, LOS ANGELES
- Signature
- /s/ Jerel Davis
- Signature date
- 08 Aug 2024
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -274,990
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Vantage II, L.P.
- Footnotes
- F1, F2
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -2,726,322
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Venture Capital V, L.P.
- Footnotes
- F1, F3
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -207,486
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Venture Capital V (Canada) LP
- Footnotes
- F1, F4
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -90,888
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Ophthalmic Affiliates Fund I, L.P.
- Footnotes
- F1, F5
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -82,006
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Affiliates Fund V, L.P.
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
Footnote F2
Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.
Footnote F3
Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein.
Footnote F4
Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.
Footnote F5
Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein.
Footnote F6
Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein.